Evotec Pins Hopes on AI Veteran as Restructuring Bites and Shareholders Lose Patience

Evotec’s annual general meeting on June 11 is shaping up as a critical juncture for the struggling biotech group. On the same day, shareholders will vote on board changes and a new compensation system, while the company simultaneously introduces a freshly appointed artificial intelligence chief. The convergence of these events underscores the depth of the turnaround challenge: the stock has lost nearly a third of its value over the past year and sits roughly 37 percent below its November 2025 peak.

The most prominent signal of a strategic pivot is the hiring of Rui Wang, a 20-year veteran of AstraZeneca, to the newly created position of Executive Vice President for global in-silico and AI solutions. His brief is to transform AI from a side project into the central engine driving Evotec’s drug discovery pipeline. For a company that has long preached the virtues of data-driven R&D, the appointment finally puts a senior executive in charge of making it happen. Yet the timing—coming as the group slashes 800 jobs and closes facilities—raises uncomfortable questions about whether the AI push is a genuine turnaround plan or a costly gamble that will take too long to pay off.

The financial picture that will greet shareholders at the AGM is sobering. First-quarter 2026 revenue dropped to €156.64 million, a fall of nearly 22 percent from the prior year. Evotec blames currency headwinds and a one-off licensing deal that inflated the year-ago figure, but the bottom line tells a starker story. The adjusted EBITDA swung to a loss of €21.9 million, while the net loss per share widened to €0.69, compared with a loss of €0.18 in the same quarter of 2025. To stem the bleeding, management booked a €75 million restructuring charge tied to the elimination of 800 roles and the closure of several sites. The aim is to achieve €75 million in structural savings by the end of 2027.

The market has reacted with deep skepticism. The stock trades at €4.85, down roughly 32 percent over the past twelve months and about 12 percent since the start of 2026. Technical indicators look uniformly bearish: the share price sits below all three key moving averages—50, 100, and 200 days—and the relative strength index of 44 suggests no clear momentum in either direction. Annualized volatility stands at nearly 45 percent, reflecting the extraordinary uncertainty baked into the equity.

Should investors sell immediately? Or is it worth buying Evotec?

Analyst opinions are as divided as the investor base. Deutsche Bank warns of further downside, setting a price target of €4.50 with a “Hold” rating. RBC Capital Markets takes the opposite view, rating the stock “Outperform” with a €10 target—a spread of more than 100 percent between two reputable firms. For most analysts covering Evotec, any positive outlook hinges on two conditions: first, that the heavy technology investments eventually deliver scalable margins, and second, that management provides far more transparent milestones after a history of delayed reporting and vague guidance. The official 2026 forecast—revenue of €700 million to €780 million and an EBITDA range of €0 to €40 million—does little to inspire confidence.

To fund the transformation, Evotec raised €116.1 million in May through a convertible bond. The injection of fresh capital supports “Project Horizon,” a multi-year expansion of capacity and technology platforms, but it also serves as a reminder that profitability remains out of reach. The debt is a bridge to a future that may or may not arrive. The key question, unspoken but central to every investor calculation, is whether that €116.1 million will carry the company through to breakeven or whether another capital round—with attendant dilution—will be needed within twelve months.

Activist pressure is already reshaping governance. MAK Capital, which holds a 7.1 percent stake, has secured a cooperation agreement with Evotec, and former Bayer executive Dieter Weinand is set to become chairman of the supervisory board, a move intended to inject more industry experience into oversight. These changes suggest the board is listening, but they also indicate that investor patience has frayed.

Evotec at a turning point? This analysis reveals what investors need to know now.

The next real test will come with the half-year results, due after the summer. By then, the initial impact of cost cuts should be visible, and Rui Wang will have had more time to outline his AI roadmap. For now, Evotec remains a high-stakes bet on a future that requires both time and capital it may not yet have enough of. The AGM gives shareholders a chance to voice their views, but the real verdict will be delivered by the numbers.

Ad

Evotec Stock: New Analysis - 9 June

Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evotec analysis...

en | DE0005664809 | EVOTEC | boerse | 69508561 |